Tumor Microenvironment and Immunotherapy for Triple-negative Breast Cancer

Overview

Journal Biomark Res

Publisher Biomed Central

Date 2024 Dec 31

PMID 39741315

Authors

Zijie Guo

Ziyu Zhu

Xixi Lin

Shenkangle Wang

Yihong Wen

Linbo Wang

Lili Zhi

Jichun Zhou

Affiliations

Soon will be listed here.

Abstract

Triple-negative breast cancer (TNBC) is a subtype of breast cancer known for its high aggressiveness and poor prognosis. Conventional treatment of TNBC is challenging due to its heterogeneity and lack of clear targets. Recent advancements in immunotherapy have shown promise in treating TNBC, with immune checkpoint therapy playing a significant role in comprehensive treatment plans. The tumor microenvironment (TME), comprising immune cells, stromal cells, and various cytokines, plays a crucial role in TNBC progression and response to immunotherapy. The high presence of tumor-infiltrating lymphocytes and immune checkpoint proteins in TNBC indicates the potential of immunotherapeutic strategies. However, the complexity of the TME, while offering therapeutic targets, requires further exploration of its multiple roles in immunotherapy. In this review, we discuss the interaction mechanism between TME and TNBC immunotherapy based on the characteristics and composition of TME, and elaborate on and analyze the effect of TME on immunotherapy, the potential of TME as an immune target, and the ability of TME as a biomarker. Understanding these dynamics will offer new insights for enhancing therapeutic approaches and investigating stratification and prognostic markers for TNBC patients.

References

Galluzzi L, Buque A, Kepp O, Zitvogel L, Kroemer G . Immunogenic cell death in cancer and infectious disease. Nat Rev Immunol. 2016; 17(2):97-111. DOI: 10.1038/nri.2016.107. View

Marabelle A, Le D, Ascierto P, Di Giacomo A, De Jesus-Acosta A, Delord J . Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. J Clin Oncol. 2019; 38(1):1-10. PMC: 8184060. DOI: 10.1200/JCO.19.02105. View

Allaoui R, Bergenfelz C, Mohlin S, Hagerling C, Salari K, Werb Z . Cancer-associated fibroblast-secreted CXCL16 attracts monocytes to promote stroma activation in triple-negative breast cancers. Nat Commun. 2016; 7:13050. PMC: 5062608. DOI: 10.1038/ncomms13050. View

Santoni M, Romagnoli E, Saladino T, Foghini L, Guarino S, Capponi M . Triple negative breast cancer: Key role of Tumor-Associated Macrophages in regulating the activity of anti-PD-1/PD-L1 agents. Biochim Biophys Acta Rev Cancer. 2017; 1869(1):78-84. DOI: 10.1016/j.bbcan.2017.10.007. View

Johnson J, Vathiotis I, Harshyne L, Ali A, Bar Ad V, Axelrod R . Nivolumab and ipilimumab in combination with radiotherapy in patients with high-risk locally advanced squamous cell carcinoma of the head and neck. J Immunother Cancer. 2023; 11(8). PMC: 10401226. DOI: 10.1136/jitc-2023-007141. View

Maude S, Laetsch T, Buechner J, Rives S, Boyer M, Bittencourt H . Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N Engl J Med. 2018; 378(5):439-448. PMC: 5996391. DOI: 10.1056/NEJMoa1709866. View

Zhu Y, Zhu X, Tang C, Guan X, Zhang W . Progress and challenges of immunotherapy in triple-negative breast cancer. Biochim Biophys Acta Rev Cancer. 2021; 1876(2):188593. DOI: 10.1016/j.bbcan.2021.188593. View

Hollmen M, Roudnicky F, Karaman S, Detmar M . Characterization of macrophage--cancer cell crosstalk in estrogen receptor positive and triple-negative breast cancer. Sci Rep. 2015; 5:9188. PMC: 4361875. DOI: 10.1038/srep09188. View

Onkar S, Cui J, Zou J, Cardello C, Cillo A, Rafid Uddin M . Immune landscape in invasive ductal and lobular breast cancer reveals a divergent macrophage-driven microenvironment. Nat Cancer. 2023; 4(4):516-534. PMC: 11194444. DOI: 10.1038/s43018-023-00527-w. View

10.

Julia E, Amante A, Pampena M, Mordoh J, Levy E . Avelumab, an IgG1 anti-PD-L1 Immune Checkpoint Inhibitor, Triggers NK Cell-Mediated Cytotoxicity and Cytokine Production Against Triple Negative Breast Cancer Cells. Front Immunol. 2018; 9:2140. PMC: 6159755. DOI: 10.3389/fimmu.2018.02140. View

11.

Piechocki M, Wu G, Jones R, Jacob J, Gibson H, Ethier S . Induction of proapoptotic antibodies to triple-negative breast cancer by vaccination with TRAIL death receptor DR5 DNA. Int J Cancer. 2012; 131(11):2562-72. PMC: 3387508. DOI: 10.1002/ijc.27534. View

12.

Schmid P, Adams S, Rugo H, Schneeweiss A, Barrios C, Iwata H . Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. N Engl J Med. 2018; 379(22):2108-2121. DOI: 10.1056/NEJMoa1809615. View

13.

Ayers M, Lunceford J, Nebozhyn M, Murphy E, Loboda A, Kaufman D . IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade. J Clin Invest. 2017; 127(8):2930-2940. PMC: 5531419. DOI: 10.1172/JCI91190. View

14.

Ferrara N . VEGF as a therapeutic target in cancer. Oncology. 2005; 69 Suppl 3:11-6. DOI: 10.1159/000088479. View

15.

Mezheyeuski A, Backman M, Mattsson J, Martin-Bernabe A, Larsson C, Hrynchyk I . An immune score reflecting pro- and anti-tumoural balance of tumour microenvironment has major prognostic impact and predicts immunotherapy response in solid cancers. EBioMedicine. 2023; 88:104452. PMC: 9918750. DOI: 10.1016/j.ebiom.2023.104452. View

16.

Adams S, Gray R, Demaria S, Goldstein L, Perez E, Shulman L . Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol. 2014; 32(27):2959-66. PMC: 4162494. DOI: 10.1200/JCO.2013.55.0491. View

17.

Fan Y, He S . The Characteristics of Tumor Microenvironment in Triple Negative Breast Cancer. Cancer Manag Res. 2022; 14:1-17. PMC: 8740624. DOI: 10.2147/CMAR.S316700. View

18.

Kumar S, Tailor D, Dheeraj A, Li W, Stefan K, Lee J . Uncovering therapeutic targets for macrophage-mediated T cell suppression and PD-L1 therapy sensitization. Cell Rep Med. 2024; 5(9):101698. PMC: 11524979. DOI: 10.1016/j.xcrm.2024.101698. View

19.

Brahmer J, Tykodi S, Chow L, Hwu W, Topalian S, Hwu P . Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012; 366(26):2455-65. PMC: 3563263. DOI: 10.1056/NEJMoa1200694. View

20.

Nanda R, Liu M, Yau C, Shatsky R, Pusztai L, Wallace A . Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial. JAMA Oncol. 2020; 6(5):676-684. PMC: 7058271. DOI: 10.1001/jamaoncol.2019.6650. View